- Posted in Business Critical | March 12, 2012 | Comments (0)
- Tags: financial, company financials, sales
- By: Julie A. Vetalice
RTI Biologics
$114.1MM, +9%
Spine $39.7MM, +17%
Sports Medicine $48.1MM, +7%
Bone Graft Substitutes/General Orthopaedic (BGS/GO) $26.2MM, +4%
4Q11 orthopaedic revenue: $28.8MM, +5%
Spine $8.6MM, -8%
Sports Medicine $13.2MM, +8%
BGS/GO $6.9MM, +22%
- Full year spine growth buoyed by mid-year stocking orders, favorable comps
- Spine business is 70%-80% Medtronic
- Expects sports med procedure increase and continued pricing pressure
- BGS/GO sales supported by U.S. sales growth, uptick in commercial distributor revenue
- BGS/GO direct distribution +47% year over year
- Expects to begin human implantation of Multipotent Adult Progenitor Cell (MAPC) technology-based implants during 2012
- Initiating large primate study for xenograft tendon to support premarketing approval application pathway in U.S.
Seikagaku (for fiscal 3Q11, ended 12/31/11)
¥7,225MM (~US $94.3MM), flat
(Performance details pertain to preceding 9 months)
- U.S. sales of Supartz rose as impact of tightening of reimbursements ran its course, increase in sales at specialty pharmacies where Supartz can be sold at comparatively high prices
- U.S. sales rose due to increased volume
- Export sales to China continue to rise, sales to Europe increased
Smith & Nephew
$3,251MM, +3%
Orthopaedics $2,312MM, +2%* (U.S. $1,204MM, +2%, Europe $622MM, -1%; Rest of World $486MM, +7%)
- Hips $705MM, -1%
- Knees $869MM, +5%
- Trauma $457MM, +3%
- Clinical Therapies $237MM, +6%
Endoscopy $939MM, +6% (U.S. $363MM, +3%; Europe $294MM, +5%; Rest of World $282MM, +12%)
- Arthroscopy $806MM, +7% (Resection +4%)
- Visualization $108MM, -7%
4Q11 orthopaedic revenue: $835MM, +2%
Orthopaedics $586MM, flat* (U.S. $311MM, flat; Europe $149MM, -7%; Rest of World $126MM, +10%)
- Hips -2% (U.S. -5%, ex-U.S. -1%)
- Knees +2% (U.S. flat, ex-U.S. +4%)
- Trauma -2% (U.S. +1%, ex-U.S. -6%)
- Clinical Therapies $61MM, +8%
Endoscopy $249MM, +7% (U.S. $97MM, +3%; Europe $79MM, +8%; Rest of World $73MM, +10%)
- Arthroscopy $MM, +9% (Repair +12%, Resection +5%)
*Revenue excludes Wound Management.
